The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I’m not, I did say Dyor, fair enough I’m staying put but all can do what they like, we all have the same interests in here.
Share buy backs and dividend means all is got well , you wouldn’t risk over paying out if the near future revenues were suppressed.
Good to talk in here about it, LTHs des some rewards and a company also needs to attract new investors like myself ,
I’ve bought 508k shares so I have my right of opinions just like the rest.
It’s in everyone’s interest to make money and I’m no different. Atb.
It will drop a bit on the 25th and then rise in the days and weeks afterwards, that’s what usually happens.
Remember the company is generating cash all the time so the value will increase also.
Offloading cash on dividend and share buybacks is a very good sign the company is doing very well and retuning cash back to its investors.
I expect regular dividend payments and so this will attract new investors along the way.atb.
You must be in by the end of trading on the 24th,
Just make sure you’re in.
I’m not selling anyway as the sp will move up towards that day and drop a little on the 25th then rise again so it’s a win win, I’ll get my 5k dividend and enjoy the sp rise.
Dyor but that’s what I’m going to do.
Obvious now that these investments are starting to give back good returns and so hence the dividend payment, you wouldn’t be doing that if they weren’t hundred percent confident in high cash revenues in the near future.
I ext divided payments coming regularly as cash flow increases.
Good to see anyway.
I’ll also be using my £5k dividend and buying more shares,
The share buyback is good thing as less shares available the higher any future dividend payments will be.
That’s fair enough but don’t you think the sp will increase rapidly especially next week as we move closer to ex dividend date on the 25th April,
1p is a big payday for all who are in so as I see it they are overflowing with cash and expecting higher revenues in the near term and its rare to see . So opportunity knocks and enjoy a company doi very well and will to share the excess cash to us all.
No question in my enlarged investment today that it’s one of my favourite investments.
This will be over 3p next week without a doubt imo.
Dyor and all the best.
Good to see a company doing very well and having excess cash reserves, also I like the fact that the board are keen to share the wealth with it’s shareholders,
Very impressed with this company and glad I bought in today.
Atb.
So will increase towards Dividend day and how I read the rns today it’s very like there’ll be many more to follow.
The company spilling over with cash flow so it has to go somewhere and so share buybacks and dividend is the best way and very pleasing for shareholders.
Sp should be a lot higher imho.
I’m very pleased that we’re moving into all possible areas to generate future revenues ,
I also love the move into the veterinary sector and potential huge revenue returns in the near term.
Very interesting proactive one to one with investors presentation.
To be fair they’re doing exactly what they intended to do this year and more.
Great listen.
https://www.google.com/search?q=proactive+investor+fusion+antibodies+plc&ie=UTF-8&oe=UTF-8&hl=en-gb&client=safari#fpstate=ive&vld=cid:14b5e405,vid:IAvbf90GgvQ,st:0
Credit
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the receipt of an R&D tax credit from HMRC in respect of the financial year ended 31 March 2023, relating to work performed on the development and optimization of the OptiMAL® platform, as well as other R&D projects in bioinformatics, antigen design and cell culture. The value of the tax credit is in line with expectations at almost £280k, which reflects the Company's continued investment in R&D projects that maintain Fusion at the forefront of technology in the antibody market. The technologies have been well received by partners and potential partners with the OptiMAL® platform notably undergoing validation through an agreement with the National Cancer Institute in the USA. Fusion will maximise the impact of the tax credit with the generation of revenue streams from the R&D projects that were supported.
Adrian Kinkaid, CEO of Fusion, said: "The R&D tax credit system is of enormous benefit to companies developing cutting edge technologies such as we continue to do at Fusion. We are now beginning to reap the benefits of the resultant technology platforms with an elevated profile in our field and anticipate considerable commercial growth to be generated from them in the coming years."